Preview

Медицинская генетика

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Семейная средиземноморская лихорадка и беременность: литературный обзор

https://doi.org/10.25557/2073-7998.2020.11.4-12

Полный текст:

Аннотация

В обзоре обобщается текущая информация о влиянии семейной средиземноморской лихорадки (ССЛ) и ее лечения на исходы беременности, анализируется вопрос гипотетической тератогенности колхицина. В случае резистентности/непереносимости колхицина обсуждается возможность использования других лекарственных средств во время беременности, в том числе, генно-инженерных биологических препаратов, среди которых при ССЛ наиболее предпочтительны ингибиторы интерлейкина 1. Представлена эволюция взглядов на необходимость проведения пренатальной диагностики хромосомных аномалий плода пациенткам с ССЛ, получающим колхицин во время зачатия и беременности, а также в тех случаях, когда колхицинотерапия проводилась мужьям во время зачатия их женами. Акцент сделан на аспектах безопасности терапии, основные положения которых представлены в клинических рекомендациях по лечению ССЛ Европейской антиревматической лиги (EULAR,2016). Согласно этим рекомендациям, прием колхицина не должен быть прекращен во время зачатия, беременности или лактации; имеющаяся на сегодняшний день доказательная база не подтверждает необходимость выполнения амниоцентеза.

Об авторе

П. О. Соцкий
Центр медицинской гeнетики и первичной охраны здоровья
Россия


Список литературы

1. Ben-Chetrit E., Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003; 62:916-919.

2. Mijatovic V., Hompes P.G., Wouters M.G. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003;108(2):171-176. doi: 10.1016/s0301-2115(02)00417-7

3. Rabinovitch O., Zemer D., Kukia E. et al. Colchicine treatment in conception and pregnancy: two hundred thirty one pregnancies in patients with Familial Mediterranean Fever. Am J Reprod Immunol. 1992; 28:245-246.

4. Ehrenfeld M., Brzezinski A., Levy M., Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol. 1987; 94(12):1186-1191. doi:10.1111/j.1471-0528.1987.tb02320.x

5. Zemer D., Pras M., Shemer Y. et al. Daily prophylactic colchicine in familial Mediterranean fever. In: Amyloid and amyloidosis. Proc 3rd International Symposium on Amyloidosis. Amsterdam-Oxford-Prinston: Exerpta Medica. 1980:580-583.

6. Michael O., Goldman R.D., Koren G. Safety of colchicine therapy during pregnancy. Can Fam Physician. 2003; 49:967-969.

7. Ben-Chetrit E., Levy M. Colchicine:1998 update. Semin Arthritis Rheum.1998;28(1):48-59. doi:10.1016/s0049-0172(98)80028-0

8. Amoura Z., Schermann J.M., Wechsler B. et al. Transplacental passage of colchicine in familial Mediterranean fever. J Rheumatol. 1994; 21(2):383.

9. Shoji R., Makino S. Preliminary notes on the teratogenic and embryocidal effects of colchicine on mouse embryos. Proc Jpn Acad. 1966; 42:822-827.

10. Berkenstadt M., Weisz B., Cuckle H. et al. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol. 2005;193:1513-6. doi:10.1016/j.ajog.2005.03.043.

11. Ditkoff E.C., Sauer M.V. Successful pregnancy in a familial Mediterranean fever patient following assisted reproduction. J Assist Reprod Genet. 1996;13(8):684-685. doi:10.1007/BF02069651.

12. Ben-Chetrit E., Ben-Chetrit A., Berkun Y., Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res. 2010; 62:(2):143-148. doi:10.1002/acr.20061.

13. Tutuncu L., Atasoyu E.M., Evrenkaya R., Mungen E. Familial mediterranean fever-related nephrotic syndrome and successful full-term pregnancy. Arch Med Res. 2006; 37(1):178-180. doi: 10.1016/j.arcmed.2005.04.013.

14. Akar Y., Yucel I., Akar M.E. et al. Long-term fluctuation of retinal sensitivity during pregnancy. Can J Ophthalmol. 2005; 40(4):487-491. doi:10.1016/S0008-4182(05)80011-0

15. Indraratna P., Virk S., Gurram D., Day R. Use of colchicine in pregnancy: A systematic review and meta-analysis. Rheumatology. (Oxford) 2018; 57(2):382-387. doi:10.1093/rheumatology/ kex353

16. Dotters-Katz S., Kuller J., Price T. The impact of familial Mediterranean fever on women’s health. Obstet Gynecol Surv. 2012; 67(6):357-64. doi:10.1097/OGX.0b013e318259ed3a

17. Yanmaz M.N., Özcan A.J., Savan K. The impact of familial Mediterranean fever on reproductive system. Clin Rheumatol. 2014; 33(10):1385-1388. doi:10.1007/s10067-014-2709-9

18. Sarı İ., Birlik M., Kasifoğlu T. Familial Mediterranean fever: An updated review. Eur J Rheumatol. 2014;1(1):21-33. doi:10.5152/eurjrheum.2014.006

19. Ozdogan H., Ugurlu S. Familial Mediterranean Fever. Presse Med. 2019;48(1):61-76. doi:10.1016/j.lpm.2018.08.014.

20. Update of the Joint European League Against Rheumatism and European Renal Association - European Dialysis and Transplant Association (EULAR/ER-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924

21. Yasar O., Iskender C., Kaymak O. et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med. 2014;27(7):733-736. doi:10.3109/14767058.2013.837446

22. Nabil H., Zayed A., State O., Badawy A. Pregnancy outcome in women with familial Mediterranean fever. J Obstet Gynaecol. 2012;32(8):756-759. doi:10.3109/01443615.2012. 698667

23. Fortunato S.J., Menon R., Lombardi S.J. Support for an infectioninduced apoptotic pathway in human fetal membranes. Am J Obstet Gynecol. 2001;184:1392-1397. doi:10.1067/mob.2001.115434

24. Romero R., Friel L.A., Velez Edwards D.R., et al. A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Am J Obstet Gynecol. 2010;203:361. doi:https://doi.org/10.1016/j.ajog.2010.05.026

25. Ofir D., Levy A., Wiznitzer A. et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2008; 141:115-118. doi:10.1016/j.ejogrb.2008.07.025

26. Shepard T.H. Catalog of teratogenic agents, 6th ed. Baltimore, MD: Johns Hopkins University Press; 1989:164-166.

27. Ferreira N.R., Buoniconti A. Trisomy after colchicine therapy. Lancet. 1968;2:1304.

28. Ben-Chetrit E., Berkun Y., Ben-Chetrit E., Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004;34(2):549-552. doi: 10.1016/j.semarthrit.2004.07.004

29. Wang X., Chen C., Wang L. et al. Conception, early pregnancy loss, and time to clinical pregnancy: a populationbased prospective study. Fertil Steril 2003;79:577-584. doi: 10.1016/s0015-0282(02)04694-0

30. Ben-Chetrit E., Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991; 20:241-246. doi:10.1016/0049-0172(91)90019-v

31. Cestari A.N., Botelho Vieira Filho J.P., Yonenaga Y. et al. A case of human reproductive abnormalities possibly induced by colchicine treatment. Rev Bras Biol. 1965;25:253.

32. Cohen M.M., Levy M., Eliakim M.A. Cytogenic evaluation of long-term colchicine therapy in the treatment of Familial Mediterranean fever (FMF). Am J Med Sci. 1977;274(2):147-152. doi:10.1097/ 00000441-197709000-00005

33. Diav-Citrin O., Shechtman S., Schwartz V. et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010;203:144. doi:10.1016/j.ajog.2010.02.063

34. Ben-Chetrit E., Scherrmann J.M., Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996;39:1213-1217. doi:10.1002/art.1780390721

35. Milunsky J.M. Breast-feeding during colchicine therapy for familial Mediterranean fever. J Pediatr. 1991;119:164. doi:10.1016/s0022-3476(05)81070-4

36. Mordel N., Birkenfeld A., Rubinger D. et al. Successful full-term pregnancy in familial Mediterranean fever complicated with amyloidosis: case report and review of the literature. Fetal Diagn Ther. 1993;8:129-134. doi:10.1159/000263761

37. Shimoni Y., Shalev E. Pregnancy and complicated familial Mediterranean fever. Int J Gynaecol Obstet. 1990;33(2):165-169. doi:10.1016/0020-7292(90)90591-8.

38. Yazicioğlu A., Turgal M., Senem O. et al. Pregnancy Outcome in Women with familial Mediterranean fever: A Retrospective Analysis of 50 Cases with a 10-Year Experience. Arch Rheumatol. 2014;29(2):94-98. doi: 10.5606/ArchRheumatol.2014.3707

39. Ozen S., Demirkaya E., Erer B. et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016;75:644-651. doi: 10.1136/annrheumdis- 2015-208690

40. İlgen U., Küçükşahin O. Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility. Eur J Rheumatol 2017;4(1):66-67. doi:10.5152/ eurjrheum.2017.16075

41. Lidar M., Yonath H., Shechter N. et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12(1):72-76. doi:10.1016/j.autrev.2012.07. 025.

42. Sönmez H.E., Batu E.D., Özen S. Familial Mediterranean fever: current perspectives. J Inflamm Res 2016;9:13-20. doi:10.2147/JIR.S91352

43. Livneh A., Cabili S., Zemer D. et al. Effect of pregnancy on renal function in amyloidosis of familial Mediterranean fever. J. Rheumatol.1993;20:1519-1523.

44. Hentgen V., Grateau G., Kone-Paut I. et al. EULAR recommendations for the practical maganement of Familial Mediterranean Fever. Seminars in arthritis and rheumatism. Elsevier 2013;387-391. doi:10.1016/j.semarthrit.2013.04.011

45. Yilmaz N.K., Kara M., Kaba M. et al. Effect of Familial Mediterranean Fever on IVF outcome: A Retrospective Case Series. Acta Clin Croat 2016; 55:254-258. doi:10.20471/acc.2016.55.02.11.

46. Ozdogan H., Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev ClinImmunol. 2017;13(5):393-404. doi:10.1080/1744666X.2017.1313116

47. Heng Y.J., Liong S., Permezel M. et al. The interplay of interleukin-1 system in pregnancy and labor. Reprod Sci. 2011;21:122-130. doi:10.1177/1933719113492204

48. Berger C.T., Recher M., Steiner U., Hauser T.M. A patient’s wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68(11):1794-1795. doi:10.1136/ard.2008.105833.

49. Chang Z., Spong C.Y., Jesus A.A. et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014; 66:3227-3232. doi: 10.1002/ art.38811

50. Fischer-Betz R., Specker C., Schneider M. Successfull outcome of two pregnancies in patients with adult onset Still’s disease treated with IL-1 receptor antagonist (anakinra) Clin Exp Rheumatol. 2011; 29:1021-1023.

51. Lachman H.J., Ozdogan H., Simon A. et al. Anti IL-1 therapies and pregnancy outcome. Pediatr Rheumatol Online J. 11(Suppl 1):A269. doi:10.1186/1546-0096-11-S1-A269

52. Ozdogan H., Ugurlu S., Ergezen B. The pregnancy outcomes in patients who are exposed to IL-1 blockade with anakinra. Ann Rheum Dis. 2015;74:400-401.

53. Youngstein T., Hoffman P., Gul A. et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology. 2017;56:2102-2108. doi:10.1093/rheumatology/ kex305


Для цитирования:


Соцкий П.О. Семейная средиземноморская лихорадка и беременность: литературный обзор. Медицинская генетика. 2020;19(11):4-12. https://doi.org/10.25557/2073-7998.2020.11.4-12

For citation:


Sotskiy P.O. Familial Mediterranean Fever (FMF) and Pregnancy: Literature Review. Medical Genetics. 2020;19(11):4-12. (In Russ.) https://doi.org/10.25557/2073-7998.2020.11.4-12

Просмотров: 123


ISSN 2073-7998 (Print)